Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Biotechnology_Personalized, Precision, Preemptive Medicines

Cernostics

Attachments

*Architects: Biotechnology_Personalized, Precision, Preemptive Medicines
*Architects: Cancer & Oncology Companies_ Devices, Technology, Imaging & Health IT
*Architects: Pathology & Microscopy (Microscopes)
*Industry: Pittsburgh, Pennsylvania
Venture Capital: Series A

Cernostics completed a Series A financing round led by Novitas Capital (Wayne, Pa.), Geisinger Health System and the Pittsburgh Life Science Greenhouse (PLSG, Pittsburgh).
Cernostics focuses on TissueCipher Pathology (TCP™)
Cernostics is discovering new ways to find, see, and treat cancer.
D. Lansing Taylor, Ph.D., CEO of Cellumen Inc. and Chairman of Cernostics.
Developing technologies that will redefine the way cancer is diagnosed.
Esophageal cancer risk test developer gets new funding (2012)
Founded 2008
Molecular diagnostics to improve esophageal cancer detection raising $500K (2012)
Personalized healthcare approach to cancer diagnosis and treatment utilizing technology and intellectual property based on a systems approach to evaluating patient tissue samples including multiplexed florescence microscopy and imaging technology
Pittsburgh, Pennsylvania
Test to determine a patient’s risk for esophageal cancer if they have Barrett’s esophagus.
Through a complex integration of quantitative pathology and advanced informatics supported by a robust electronic medical record management system